Fact Check: Is Compounded Semaglutide 'Just as Effective' as Wegovy?

Compounded semaglutide is marketed as 'just as effective' as Wegovy. Here's what the actual evidence says, what's missing, and where the honest answer lies.

One of the most repeated claims in GLP-1 telehealth marketing has been that compounded semaglutide is "just as effective" as Wegovy or Ozempic because it is the same active ingredient. The claim is intuitive but glosses over significant evidentiary and regulatory nuance. This source check pulls the actual evidence on what we know — and don't know — about the comparative effectiveness of compounded and brand-name semaglutide.

The short answer is that the active ingredient is the same, but "same active ingredient" does not mean "equivalent clinical outcomes." Brand-name semaglutide has been studied in tens of thousands of patients across the STEP, SUSTAIN, SELECT, and FLOW trial programs. Compounded semaglutide has no comparable clinical trial evidence.

What "Just as Effective" Actually Claims

There are three distinct claims bundled under "just as effective." First, that the chemical structure of the semaglutide peptide in compounded products is identical to the patented molecule. Second, that the pharmacokinetic profile — how the drug is absorbed, distributed, metabolized, and eliminated — is equivalent. Third, that patient clinical outcomes (weight loss, glycemic control, cardiovascular risk reduction) are equivalent.

The first claim is often true in practice, though impurity profiles and manufacturing consistency can vary. The second claim depends heavily on formulation, excipients, and delivery device. The third claim is where the evidence gap is largest — no head-to-head clinical trial data exists.

The Published Evidence Base

This is not a pedantic distinction. The clinical benefits patients seek — sustained weight loss, cardiovascular protection, kidney protection — were established in trials using specific brand-name formulations at specific doses administered in specific ways. Compounded products replicate the active ingredient but do not replicate the studied formulation, the dose titration schedule, or the trial conditions.

What Compounded Evidence Actually Exists

There is observational and anecdotal evidence from telehealth patient cohorts. Several telehealth brands have published or presented internal data showing weight loss outcomes among their compounded semaglutide patients. These data are not worthless, but they are not equivalent to randomized controlled trial evidence. They lack control groups, suffer from selection and survivorship bias, and are generally not published in peer-reviewed journals under standard reporting frameworks.

Impurity and Manufacturing Variation

The FDA has published data on peptide impurities found in some compounded semaglutide samples. The agency's 2023 and 2024 testing programs identified products with higher-than-expected impurity levels, incorrect salt forms, and in some cases active ingredient concentrations that didn't match label claims. These findings don't implicate every compounding pharmacy, but they do illustrate why "same active ingredient" is an oversimplification.

Brand-name semaglutide is manufactured under strict FDA Good Manufacturing Practice (GMP) standards, with rigorous quality control across batches. Compounded products are manufactured under 503A or 503B standards, which are substantial but not identical to commercial GMP for FDA-approved drugs.

The Honest Answer

For patients who received benefit from compounded semaglutide, the drug worked. That is real. But the claim of equivalence to brand-name Wegovy is a marketing claim rather than an evidentiary one. With Wegovy now available at $349/month cash-pay through NovoCare and $249/month through authorized telehealth subscription, the price gap that previously justified the evidentiary tradeoff has narrowed significantly. For more, see our pricing timeline and SELECT trial 5-year follow-up review.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.